Annual EBITDA
-$193.94 M
+$61.64 M+24.12%
December 31, 2023
Summary
- As of February 7, 2025, CHRS annual EBITDA is -$193.94 million, with the most recent change of +$61.64 million (+24.12%) on December 31, 2023.
- During the last 3 years, CHRS annual EBITDA has fallen by -$353.70 million (-221.39%).
- CHRS annual EBITDA is now -221.39% below its all-time high of $159.76 million, reached on December 31, 2020.
Performance
CHRS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$3.84 M
+$2.56 M+40.00%
September 30, 2024
Summary
- As of February 7, 2025, CHRS quarterly EBITDA is -$3.84 million, with the most recent change of +$2.56 million (+40.00%) on September 30, 2024.
- Over the past year, CHRS quarterly EBITDA has increased by +$25.01 million (+86.69%).
- CHRS quarterly EBITDA is now -103.32% below its all-time high of $115.50 million, reached on March 31, 2024.
Performance
CHRS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$37.29 M
+$25.01 M+203.81%
September 30, 2024
Summary
- As of February 7, 2025, CHRS TTM EBITDA is $37.29 million, with the most recent change of +$25.01 million (+203.81%) on September 30, 2024.
- Over the past year, CHRS TTM EBITDA has increased by +$211.69 million (+121.38%).
- CHRS TTM EBITDA is now -82.08% below its all-time high of $208.03 million, reached on June 30, 2020.
Performance
CHRS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CHRS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.1% | +86.7% | +121.4% |
| 3 y3 years | -221.4% | +88.0% | +116.7% |
| 5 y5 years | +1.3% | +88.0% | +116.7% |
CHRS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.6% | -103.3% | +95.5% | at high | +114.3% |
| 5 y | 5-year | -221.4% | +25.6% | -103.3% | +97.7% | -82.1% | +114.3% |
| alltime | all time | -221.4% | +25.6% | -103.3% | +97.7% | -82.1% | +114.3% |
Coherus BioSciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.84 M(-40.0%) | $37.29 M(+203.8%) |
| Jun 2024 | - | -$6.40 M(-105.5%) | $12.27 M(-191.8%) |
| Mar 2024 | - | $115.50 M(-269.9%) | -$13.37 M(-93.1%) |
| Dec 2023 | -$193.94 M(-24.1%) | -$67.97 M(+135.6%) | -$193.94 M(+11.2%) |
| Sep 2023 | - | -$28.85 M(-10.0%) | -$174.40 M(-22.0%) |
| Jun 2023 | - | -$32.05 M(-50.7%) | -$223.66 M(-4.5%) |
| Mar 2023 | - | -$65.07 M(+34.3%) | -$234.30 M(-8.3%) |
| Dec 2022 | -$255.58 M(-2.0%) | -$48.44 M(-38.0%) | -$255.58 M(+3.8%) |
| Sep 2022 | - | -$78.11 M(+83.0%) | -$246.24 M(+23.1%) |
| Jun 2022 | - | -$42.68 M(-50.6%) | -$199.99 M(+10.7%) |
| Mar 2022 | - | -$86.35 M(+120.9%) | -$180.59 M(-30.7%) |
| Dec 2021 | -$260.69 M(-263.2%) | -$39.10 M(+22.7%) | -$260.69 M(+27.6%) |
| Sep 2021 | - | -$31.86 M(+36.9%) | -$204.32 M(+48.1%) |
| Jun 2021 | - | -$23.28 M(-86.0%) | -$137.99 M(+186.1%) |
| Mar 2021 | - | -$166.45 M(-1063.8%) | -$48.23 M(-130.2%) |
| Dec 2020 | $159.76 M(+40.6%) | $17.27 M(-49.9%) | $159.76 M(-15.6%) |
| Sep 2020 | - | $34.47 M(-48.2%) | $189.30 M(-9.0%) |
| Jun 2020 | - | $66.48 M(+60.0%) | $208.03 M(+22.2%) |
| Mar 2020 | - | $41.54 M(-11.2%) | $170.28 M(+49.8%) |
| Dec 2019 | $113.64 M(-157.8%) | $46.81 M(-12.0%) | $113.64 M(+1461.6%) |
| Sep 2019 | - | $53.20 M(+85.2%) | $7.28 M(-107.2%) |
| Jun 2019 | - | $28.73 M(-290.3%) | -$101.52 M(-40.5%) |
| Mar 2019 | - | -$15.10 M(-74.6%) | -$170.62 M(-13.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$196.49 M(-12.8%) | -$59.55 M(+7.1%) | -$196.49 M(+7.6%) |
| Sep 2018 | - | -$55.60 M(+37.7%) | -$182.68 M(-0.1%) |
| Jun 2018 | - | -$40.37 M(-1.5%) | -$182.91 M(-6.1%) |
| Mar 2018 | - | -$40.97 M(-10.4%) | -$194.73 M(-13.6%) |
| Dec 2017 | -$225.34 M(+92.9%) | -$45.74 M(-18.1%) | -$225.34 M(-10.7%) |
| Sep 2017 | - | -$55.83 M(+7.0%) | -$252.37 M(+130.4%) |
| Jun 2017 | - | -$52.18 M(-27.1%) | -$109.52 M(-12.0%) |
| Mar 2017 | - | -$71.58 M(-1.6%) | -$124.41 M(+6.5%) |
| Dec 2016 | -$116.81 M(-47.4%) | -$72.78 M(-183.6%) | -$116.81 M(+21.7%) |
| Sep 2016 | - | $87.02 M(-229.7%) | -$96.01 M(-62.2%) |
| Jun 2016 | - | -$67.07 M(+4.8%) | -$253.85 M(+3.4%) |
| Mar 2016 | - | -$63.98 M(+23.1%) | -$245.41 M(+10.5%) |
| Dec 2015 | -$222.04 M(+168.8%) | -$51.98 M(-26.6%) | -$222.04 M(+11.7%) |
| Sep 2015 | - | -$70.82 M(+20.8%) | -$198.84 M(+46.5%) |
| Jun 2015 | - | -$58.63 M(+44.4%) | -$135.75 M(+34.5%) |
| Mar 2015 | - | -$40.61 M(+41.1%) | -$100.90 M(+22.1%) |
| Dec 2014 | -$82.60 M(+72.3%) | -$28.79 M(+272.9%) | -$82.60 M(+27.1%) |
| Sep 2014 | - | -$7.72 M(-67.5%) | -$65.00 M(-15.2%) |
| Jun 2014 | - | -$23.78 M(+6.6%) | -$76.66 M(+45.0%) |
| Mar 2014 | - | -$22.31 M(+99.5%) | -$52.88 M(+73.0%) |
| Dec 2013 | -$47.94 M(+53.2%) | -$11.18 M(-42.3%) | -$30.56 M(+57.7%) |
| Sep 2013 | - | -$19.38 M | -$19.38 M |
| Dec 2012 | -$31.28 M | - | - |
FAQ
- What is Coherus BioSciences annual EBITDA?
- What is the all time high annual EBITDA for Coherus BioSciences?
- What is Coherus BioSciences annual EBITDA year-on-year change?
- What is Coherus BioSciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Coherus BioSciences?
- What is Coherus BioSciences quarterly EBITDA year-on-year change?
- What is Coherus BioSciences TTM EBITDA?
- What is the all time high TTM EBITDA for Coherus BioSciences?
- What is Coherus BioSciences TTM EBITDA year-on-year change?
What is Coherus BioSciences annual EBITDA?
The current annual EBITDA of CHRS is -$193.94 M
What is the all time high annual EBITDA for Coherus BioSciences?
Coherus BioSciences all-time high annual EBITDA is $159.76 M
What is Coherus BioSciences annual EBITDA year-on-year change?
Over the past year, CHRS annual EBITDA has changed by +$61.64 M (+24.12%)
What is Coherus BioSciences quarterly EBITDA?
The current quarterly EBITDA of CHRS is -$3.84 M
What is the all time high quarterly EBITDA for Coherus BioSciences?
Coherus BioSciences all-time high quarterly EBITDA is $115.50 M
What is Coherus BioSciences quarterly EBITDA year-on-year change?
Over the past year, CHRS quarterly EBITDA has changed by +$25.01 M (+86.69%)
What is Coherus BioSciences TTM EBITDA?
The current TTM EBITDA of CHRS is $37.29 M
What is the all time high TTM EBITDA for Coherus BioSciences?
Coherus BioSciences all-time high TTM EBITDA is $208.03 M
What is Coherus BioSciences TTM EBITDA year-on-year change?
Over the past year, CHRS TTM EBITDA has changed by +$211.69 M (+121.38%)